/

ITRMF

Iterum Therapeutics plcClosed

0.0000100.00 0.00%USD

OTC Markets OTCPK · as of Oct 12, 16:00 ET · 15m delay

Open

0.0249

Prev close

0.000010

Day range

0.02400.0249

52-week range

0.0000100.7980

Volume

26.21K1.41×

Mkt cap

532

P/E ttm

—

Fwd P/E

—

EPS ttm

-7.20

Div yield

0.00%

Earnings

—

From 52w high

−100.00%

Price Chart

Yahoo Finance · delayed

ITRMFOct 12, 2026O 0.0000H 0.0000L 0.0000C 0.00000.0000 (0.00%)

SMA 500.0000
SMA 2000.1103

1Y change −100.00% since Oct 13, 2025 close532 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ITRMF Iterum Therapeutics plc · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: 0.00%
1 month: 0.00%
3 months: −99.98%
6 months: −99.94%
Year to date: −100.00%
1 year: −100.00%

Valuation & ownership

Market cap: 532
Enterprise value: 22.73M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: —
Price / sales (ttm): 0.00
EV / EBITDA: -1.18
EPS (ttm): -7.20
EPS (forward): —
Beta (5y monthly): 3.82
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 53.29M
Float: 52.37M
Short % of float: 5.80%
Short ratio (days): 2.36
Held by insiders: 0.78%
Held by institutions: 0.52%
Avg volume (3m): 18.62K
50-day average: 0.000012
200-day average: 0.0945
52-week change: −100.00%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 32.6
vs 50-day SMA: −15.25%
vs 200-day SMA: −99.99%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 3484.88%
Realised vol (20d, ann.): 0.0%
From 52-week high: −100.00%
From 52-week low: 0.00%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 390.00K
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 29.74%
Operating margin: -1982.31%
Profit margin: 0.00%

DES

About Iterum Therapeutics plc

Yahoo Finance profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics plc is in reorganization.

Sector: Healthcare
Industry: Biotechnology
Employees: 9
Headquarters: Dublin, Ireland
Website: iterumtx.com
Officers: Dr. Michael W. Dunne M.D. Strategic Advisor & Director
Mr. Tom Loughman Ph.D. Senior Vice President of Technical Operations
Kevin Dalton Senior Director of Legal Affairs & Company Secretary

SEAS

Seasonality · ITRMF

2018–2026 · monthly returns

Strongest month Nov +28.44%Weakest month Oct −14.52%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-8.4	-13.8	-88.7	0.0	163.3	-36.8	-99.8	-90.0	0.0	0.0			−100.0%
2025	-9.6	-12.8	-11.8	-8.9	-10.7	-0.5	-26.5	-7.4	-1.0	0.0	-31.3	-27.2	−81.1%
2024	-21.8	-19.5	24.2	-0.6	-2.0	-23.7	4.4	-1.3	-7.6	18.3	56.6	-12.4	−10.2%
2023	65.5	-18.0	-12.3	17.0	-1.7	-7.0	-0.9	-17.0	-9.0	-18.4	187.7	4.8	+134.5%
2022	-12.6	16.5	-11.0	-28.5	-9.4	-13.0	9.9	-20.0	-38.6	4.3	-23.1	-35.4	−85.7%
2021	42.6	16.3	-14.0	-12.8	17.9	59.3	-66.3	-14.0	-16.7	-4.4	-8.1	-20.2	−60.4%
2020	-48.4	3.4	12.9	29.2	20.3	-71.7	-12.6	-25.0	34.6	-54.9	54.4	35.1	−78.0%
2019	22.6	-7.7	39.7	2.2	-22.7	9.9	-4.8	-4.6	-7.7	-53.2	-11.5	88.3	−10.2%
2018						-6.7	-12.9	8.3	-34.1	-8.0	2.9	-20.1	−56.2%

INSD

Insider Activity · ITRMF

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Nov 17, 2025	Dunne Michael WDirector	Purchase at price 0.37 per share.	6K	$2.19K
Aug 7, 2025	Dunne Michael WDirector	Purchase at price 0.72 per share.	15K	$10.85K

ITRMF

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ITRMF

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Iterum Therapeutics plc

Seasonality · ITRMF

Insider Activity · ITRMF

Congress Trades · ITRMF

Investors Holding ITRMF

Investors Holding ITRMF

Congress Trades · ITRMF

Insider Activity · ITRMF

Seasonality · ITRMF

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Iterum Therapeutics plc

Earnings & Dividends

News